UB Paderborn / Katalog / Suche / in CDI

Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment

Endocrine-related cancer, 2011-10, Vol.18 (5), p.565-577

2011

Volltextzugriff (PDF)

Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype

Annals of oncology, 2015-08, Vol.26 (8), p.1685-1691

2015

Volltextzugriff (PDF)

Effect of delays in time to fixation due to routine X-ray of surgical breast cancer specimens on gene expression profiles

Annals of oncology, 2015-05, Vol.26, p.iii10-iii10

2015

Volltextzugriff (PDF)

FGFR3 and Tp53 Mutations in T1G3 Transitional Bladder Carcinomas: Independent Distribution and Lack of Association with Prognosis

Clinical cancer research, 2005-08, Vol.11 (15), p.5444-5450

2005

Volltextzugriff (PDF)

Abstract S6-02: Occurrence of natural ESR1 mutations during acquisition of endocrine resistance in breast cancers and widely used ER+ cell lines

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.S6-S6-02

2016

Volltextzugriff (PDF)

Oestrogen module of 21-gene recurrence score predicts increased late recurrence for ER+HER2- breast cancer

European journal of cancer (1990), 2014-03, Vol.50, p.S105-S106

2014

Volltextzugriff (PDF)

Relationship of PIK3CA Mutation and PI3K Pathway Activity with Antiproliferative Response to Anastrozole in Er+ Breast Cancer

Annals of oncology, 2013-05, Vol.24, p.iii29

2013

Volltextzugriff (PDF)

S4-5: Comparison of PAM50 Risk of Recurrence (ROR) Score with OncotypeDx and IHC4 for Predicting Residual Risk of RFS and Distant-(D)RFS after Endocrine Therapy: A TransATAC Study

Cancer research (Chicago, Ill.), 2011-12, Vol.71 (24_Supplement), p.S4-S4-5

2011

Volltextzugriff (PDF)

PI3K Pathway Activation in Breast Cancer Is Associated with the Basal-Like Phenotype and Cancer-Specific Mortality

Cancer research (Chicago, Ill.), 2009-12, Vol.69 (24_Supplement), p.2123-2123

2009

Volltextzugriff (PDF)

P1-06-02: Correlation between Gene Variants in CYP19 (Aromatase) and TCL1A with Disease and Tolerability Endpoints in the ATAC Trial

Cancer research (Chicago, Ill.), 2011-12, Vol.71 (24_Supplement), p.P1-P1-06-02

2011

Volltextzugriff (PDF)

Aberrent hedgehog signaling is an early event in breast cancer development

Cancer research (Chicago, Ill.), 2009-01, Vol.69 (2_Supplement), p.24

2009

Volltextzugriff (PDF)

Abstract PD5-05: Genomic instability and poor antiproliferative response to aromatase inhibitor treatment: A POETIC study

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.PD5-05-PD5-05

2018

Volltextzugriff (PDF)

Air Pollution and Tp53 Mutations in Bladder Cancer In Spain

Epidemiology (Cambridge, Mass.), 2006-11, Vol.17 (Suppl), p.S366

2006

Volltextzugriff (PDF)

Abstract P2-09-02: True effect of aromatase inhibitor (AI) treatment on global gene expression (expr) changes in postmenopausal ER+ breast cancer (BC) patients: A POETIC study (CRUK/07/015)

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P2-P2-09-02

2017

Volltextzugriff (PDF)

Abstract P2-10-02: The impact of intrinsic subtypes and molecular features on aromatase inhibitor induced reduction of proliferation marker of Ki67 in primary ER+ breast cancer: A POETIC study (CRUK/07/015)

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P2-P2-10-02

2017

Volltextzugriff (PDF)

Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population

The lancet oncology, 2013-10, Vol.14 (11), p.1067-1076

2013

Volltextzugriff (PDF)

Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers

Proceedings of the National Academy of Sciences - PNAS, 2010-12, Vol.107 (51), p.22231-22236

2010

Volltextzugriff (PDF)

PIK3CA MUTATIONS ARE AN EARLY GENETIC ALTERATION ASSOCIATED WITH FGFR3 MUTATIONS IN SUPERFICIAL PAPILLARY BLADDER TUMORS

European urology supplements : official journal of the European Association of Urology, 2006-09, Vol.5 (14), p.808-808

2006

Volltextzugriff (PDF)

FGFR3 MUTATIONS AND FGFR3 PROTEIN OVEREXPRESSION IN SUPERFICIAL BLADDER TUMORS

European urology supplements : official journal of the European Association of Urology, 2006-09, Vol.5 (14), p.808-808

2006

Volltextzugriff (PDF)

Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor-positive Breast Cancers

Clinical cancer research, 2022-03, Vol.28 (6), p.1217-1228

2022

Volltextzugriff (PDF)

Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer

Science translational medicine, 2015-11, Vol.7 (313), p.313ra182

2015

Volltextzugriff (PDF)

HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer

EBioMedicine, 2022-09, Vol.83, p.104205-104205, Article 104205

2022

Volltextzugriff (PDF)

Abstract 926: ESR1 mutations evolve during the treatment of metastatic breast cancer, and detection in ctDNA predicts sensitivity to subsequent hormone therapy

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.926-926

2015

Volltextzugriff (PDF)

Prediction of late distant recurrence in estrogen receptor positive breast cancer patients: prospective comparison of the Breast Cancer Index (BCI), Oncotype DX recurrence score, and IHC4 in TransATAC

The lancet oncology, 2013-09, Vol.14 (11), p.1067-1076

2013

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment

Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype

Effect of delays in time to fixation due to routine X-ray of surgical breast cancer specimens on gene expression profiles

FGFR3 and Tp53 Mutations in T1G3 Transitional Bladder Carcinomas: Independent Distribution and Lack of Association with Prognosis

Abstract S6-02: Occurrence of natural ESR1 mutations during acquisition of endocrine resistance in breast cancers and widely used ER+ cell lines

Oestrogen module of 21-gene recurrence score predicts increased late recurrence for ER+HER2- breast cancer

Relationship of PIK3CA Mutation and PI3K Pathway Activity with Antiproliferative Response to Anastrozole in Er+ Breast Cancer

S4-5: Comparison of PAM50 Risk of Recurrence (ROR) Score with OncotypeDx and IHC4 for Predicting Residual Risk of RFS and Distant-(D)RFS after Endocrine Therapy: A TransATAC Study

PI3K Pathway Activation in Breast Cancer Is Associated with the Basal-Like Phenotype and Cancer-Specific Mortality

P1-06-02: Correlation between Gene Variants in CYP19 (Aromatase) and TCL1A with Disease and Tolerability Endpoints in the ATAC Trial

Aberrent hedgehog signaling is an early event in breast cancer development

Abstract PD5-05: Genomic instability and poor antiproliferative response to aromatase inhibitor treatment: A POETIC study

Air Pollution and Tp53 Mutations in Bladder Cancer In Spain

Abstract P2-09-02: True effect of aromatase inhibitor (AI) treatment on global gene expression (expr) changes in postmenopausal ER+ breast cancer (BC) patients: A POETIC study (CRUK/07/015)

Abstract P2-10-02: The impact of intrinsic subtypes and molecular features on aromatase inhibitor induced reduction of proliferation marker of Ki67 in primary ER+ breast cancer: A POETIC study (CRUK/07/015)

Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population

Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers

PIK3CA MUTATIONS ARE AN EARLY GENETIC ALTERATION ASSOCIATED WITH FGFR3 MUTATIONS IN SUPERFICIAL PAPILLARY BLADDER TUMORS

FGFR3 MUTATIONS AND FGFR3 PROTEIN OVEREXPRESSION IN SUPERFICIAL BLADDER TUMORS

Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor-positive Breast Cancers

Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer

HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer

Abstract 926: ESR1 mutations evolve during the treatment of metastatic breast cancer, and detection in ctDNA predicts sensitivity to subsequent hormone therapy

Prediction of late distant recurrence in estrogen receptor positive breast cancer patients: prospective comparison of the Breast Cancer Index (BCI), Oncotype DX recurrence score, and IHC4 in TransATAC

Suchergebnisse filtern